Literature DB >> 32215750

Challenging the Relevance of Unbound Tissue-to-Blood Partition Coefficient (Kpuu) on Prediction of Drug-Drug Interactions.

Jasleen K Sodhi1, Shuaibing Liu2, Leslie Z Benet3.   

Abstract

PURPOSE: To examine the theoretical/practical utility of the liver-to-blood partition coefficient (Kpuu) for predicting drug-drug interactions (DDIs), and compare the Kpuu-approach to the extended clearance concept AUCR-approach.
METHODS: The Kpuu relationship was derived from first principles. Theoretical simulations investigated the impact of changes in a single hepatic-disposition process on unbound systemic (AUCB,u) and hepatic exposure (AUCH,u) versus Kpuu. Practical aspects regarding Kpuu utilization were examined by predicting the magnitude of DDI between ketoconazole and midazolam employing published ketoconazole Kpuu values.
RESULTS: The Kpuu hepatic-disposition relationship is based on the well-stirred model. Simulations emphasize that changes in influx/efflux intrinsic clearances result in Kpuu changes, however AUCH,u remains unchanged. Although incorporation of Kpuu is believed to improve DDI-predictions, utilizing published ketoconazole Kpuu values resulted in prediction errors for a midazolam DDI.
CONCLUSIONS: There is limited benefit in using Kpuu for DDI-predictions as the AUCR-based approach can reasonably predict DDIs without measurement of intracellular drug concentrations, a difficult task hindered by experimental variability. Further, Kpuu changes can mislead as they may not correlate with changes in AUCB,u or AUCH,u. The well-stirred model basis of Kpuu when applied to hepatic-disposition implies that nuances of intracellular drug distribution are not considered by the Kpuu model.

Entities:  

Keywords:  Kpuu; drug-drug interactions; liver-to-blood partitioning; well-stirred model

Mesh:

Substances:

Year:  2020        PMID: 32215750      PMCID: PMC7518636          DOI: 10.1007/s11095-020-02797-w

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  30 in total

1.  Serum binding of ketoconazole in health and disease.

Authors:  R Martínez-Jordá; J M Rodriguez-Sasiain; E Suárez; R Calvo
Journal:  Int J Clin Pharmacol Res       Date:  1990

Review 2.  In vitro-in vivo extrapolation of hepatic clearance involving active uptake: theoretical and experimental aspects.

Authors:  P J H Webborn; A J Parker; R L Denton; R J Riley
Journal:  Xenobiotica       Date:  2007 Oct-Nov       Impact factor: 1.908

3.  Theoretical Considerations for Direct Translation of Unbound Liver-to-Plasma Partition Coefficient from In Vitro to In Vivo.

Authors:  Zhenhong Li; Li Di; Tristan S Maurer
Journal:  AAPS J       Date:  2019-03-18       Impact factor: 4.009

Review 4.  Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond.

Authors:  Hugh A Barton; Yurong Lai; Theunis C Goosen; Hannah M Jones; Ayman F El-Kattan; James R Gosset; Jian Lin; Manthena V Varma
Journal:  Expert Opin Drug Metab Toxicol       Date:  2013-01-21       Impact factor: 4.481

5.  Mechanistic understanding of brain drug disposition to optimize the selection of potential neurotherapeutics in drug discovery.

Authors:  Irena Loryan; Vikash Sinha; Claire Mackie; Achiel Van Peer; Wilhelmus Drinkenburg; An Vermeulen; Denise Morrison; Mario Monshouwer; Donald Heald; Margareta Hammarlund-Udenaes
Journal:  Pharm Res       Date:  2014-03-13       Impact factor: 4.200

Review 6.  How Transporters Have Changed Basic Pharmacokinetic Understanding.

Authors:  Leslie Z Benet; Christine M Bowman; Jasleen K Sodhi
Journal:  AAPS J       Date:  2019-09-03       Impact factor: 4.009

7.  Assessing the Risk of Drug-Induced Cholestasis Using Unbound Intrahepatic Concentrations.

Authors:  Julia Riede; Birk Poller; Jörg Huwyler; Gian Camenisch
Journal:  Drug Metab Dispos       Date:  2017-03-02       Impact factor: 3.922

8.  A Novel Unified Approach to Predict Human Hepatic Clearance for Both Enzyme- and Transporter-Mediated Mechanisms Using Suspended Human Hepatocytes.

Authors:  Keith A Riccardi; David A Tess; Jian Lin; Roshan Patel; Sangwoo Ryu; Karen Atkinson; Li Di; Rui Li
Journal:  Drug Metab Dispos       Date:  2019-02-20       Impact factor: 3.922

9.  The Extended Clearance Concept Following Oral and Intravenous Dosing: Theory and Critical Analyses.

Authors:  Leslie Z Benet; Christine M Bowman; Shufang Liu; Jasleen K Sodhi
Journal:  Pharm Res       Date:  2018-10-22       Impact factor: 4.200

10.  Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential.

Authors:  Michael Gertz; Catherine M Cartwright; Michael J Hobbs; Kathryn E Kenworthy; Malcolm Rowland; J Brian Houston; Aleksandra Galetin
Journal:  Pharm Res       Date:  2012-11-22       Impact factor: 4.200

View more
  4 in total

Review 1.  Can In Vitro-In Vivo Extrapolation Be Successful? Recognizing the Incorrect Clearance Assumptions.

Authors:  Leslie Z Benet; Jasleen K Sodhi
Journal:  Clin Pharmacol Ther       Date:  2021-12-08       Impact factor: 6.903

Review 2.  Successful and Unsuccessful Prediction of Human Hepatic Clearance for Lead Optimization.

Authors:  Jasleen K Sodhi; Leslie Z Benet
Journal:  J Med Chem       Date:  2021-03-25       Impact factor: 7.446

3.  There is Only One Valid Definition of Clearance: Critical Examination of Clearance Concepts Reveals the Potential for Errors in Clinical Drug Dosing Decisions.

Authors:  Leslie Z Benet; Jasleen K Sodhi; George Makrygiorgos; Ali Mesbah
Journal:  AAPS J       Date:  2021-05-10       Impact factor: 4.009

4.  Recent developments in in vitro and in vivo models for improved translation of preclinical pharmacokinetics and pharmacodynamics data.

Authors:  Jaydeep Yadav; Mehdi El Hassani; Jasleen Sodhi; Volker M Lauschke; Jessica H Hartman; Laura E Russell
Journal:  Drug Metab Rev       Date:  2021-05-25       Impact factor: 6.984

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.